Physiological Effects of ANGPTL3 Variants in Humans
ConditionHypocholesterolemia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Pennsylvania
About this trial
To evaluate the role of ANGPTL3, on lipid metabolism. To explore the role of this protein on glucose metabolism.
Eligibility criteria
Qualifiers
Subjects aged 18 or older meeting at least one of the following criteria
Carrying genetic variants in the gene encoding for ANGPTL3,
Unaffected controls matched for age, race, gender,
Willing to follow study procedures
Disqualifiers
Any medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study, or confound the study data
Taking any medication that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study, or confound the study data
Women that are pregnant or nursing
History of liver disease or abnormal liver function tests (>2x upper limit of normal)
Trial design
Treatments tested in this trial
- Kinetics test, oral fat tolerance test, and an oral glucose tolerance test.
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Pennsylvania
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Source ClinicalTrials.gov